Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Colombia (outCome)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms outCome
- Sponsors AbbVie
- 15 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Aug 2017 Planned End Date changed from 20 Dec 2017 to 30 Jun 2018.
- 15 Aug 2017 Planned primary completion date changed from 20 Dec 2017 to 30 Jun 2018.